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Abstract
During late fetal life, Schwann cells in the peripheral nerves, singled out by the larger axons will
transit through a promyelinating stage before exiting the cell cycle and initiating myelin formation.
A network of extra- and intracellular signaling pathways, regulating a transcriptional program of cell
differentiation, governs this progression of cellular changes, culminating in a highly differentiated
cell. In this review we focus on the roles of a number of transcription factors not only in myelination,
during normal development, but also in demyelination, following nerve trauma. These factors include
specification factors involved in early development of Schwann cells from neural crest (Sox10) as
well as factors specifically required for transitions into the promyelinating and myelinating stages
(Oct6/Scip and Krox20/Egr2). From this description we can glean the first, still very incomplete,
contours of a gene regulatory network that governs myelination and demyelination during
development and regeneration.
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Transcriptional control of myelination and demyelination
Myelination promoting signals (discussed in other reviews in this special issue of Glia)
converge on a number of transcription factors to drive the transition of immature,
promyelinating proliferative cells to myelinating cells. Over the last decade several
transcription factors were found to play key roles in this transition and the execution of a
transcriptional program directing myelination. These transcription factors, their regulatory
relationships and the intracellular signaling pathways that modulate their activity have been
studied with growing intensity over the last few years. These studies have revealed a number
of regulatory circuits that outline the contours of a gene regulatory network of myelination in
the peripheral nervous system. A simplified outline of this network is depicted in Figure 1. A
myelination promoting circuit, consisting of the POU domain factors Oct6/Scip, Brn2 and
Sox10 that regulate Krox20/Egr2 and drives the promyelinating to myelinating transition,
forms the backbone of this regulatory network. More recently, a second cross-antagonistic
circuit of Krox20/Egr2 versus cJun and Sox2 has been described that governs active
demyelination following nerve trauma. In the following sections we will discuss the different
transcription factors, their mechanism of action and their regulatory relationships.
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Major transcriptional regulators of the myelination process: Oct6/Scip,
Krox20/Egr2 and Sox10
The POU homeo-domain transcription factors Oct6/Scip and Brn2 are important Schwann cell
autonomous regulators of the timing and rate of the promyelin to myelinating transition
(Bermingham et al. 1996; Jaegle et al. 2003; Jaegle et al. 1996). While in normal rodent nerves,
the vast majority of myelination competent Schwann cells make this transition in the first week
of postnatal life, Oct6/Scip mutant Schwann cells initiate this transition with 1–2 days delay
and do so with altered kinetics (Figure 2). Deletion of both Oct6/Scip and Brn2 results in a
more severe phenotype with persistence of promyelin Schwann cells into adulthood and
hypomyelinated axons.
A major target of Oct6/Brn2 regulation is the immediate early gene Krox20/Egr2. Previous
mouse knockout studies had identified Krox20/Egr2 as a transcription factor required for the
myelinating phase of Schwann cell development (Topilko et al. 1994). Peripheral nerve from
Krox20/Egr2 null mice exhibits lower levels of several major myelin genes with Schwann cells
arrested at the promyelin stage, failing to enter the myelinating phase of cell differentiation.
Independent analysis of a mouse with a hypomorphic Krox20/Egr2 allele (Egr2 Lo/Lo)
confirmed these initial observations (Le et al. 2005a). Furthermore, it was recently
demonstrated that Krox20/Egr2 is also required for maintenance of peripheral nerve
myelination (Decker et al. 2006).
Additional critical insight into the transcriptional regulation of myelination resulted from
identification of the HMG box–containing Sox10 transcription factor as an integral mediator
of Schwann cell differentiation. Sox10 is specifically expressed in Schwann cells and other
neural crest–derived tissues and is required for Schwann cell specification from the neural crest
(Britsch et al. 2001; Kuhlbrodt et al. 1998b). Sox10 belongs to the E class of Sox factors, which
also includes Sox8 and Sox9 (reviewed in Wegner and Stolt 2005). Indeed, recent work from
the Wegner group has uncovered functional redundancy in specific developmental contexts,
including oligodendrocyte differentiation (Finzsch et al. 2008; Stolt et al. 2004). However,
Sox10 appears to be the preeminent member of this family regulating Schwann cell
development.
Feedforward coordination of commitment to myelination
As mentioned above, the zinc finger transcription factor Krox20/Egr2 is a major target of Oct6/
Brn2 regulation. Activation of Krox20/Egr2 transcription in Schwann cells is mediated through
a cis-acting element in the Krox20/Egr2 locus called the myelin-associated Schwann cell
enhancer or mSCE (Ghislain and Charnay 2006; Ghislain et al. 2002). Co-transfection
experiments have shown that Oct6/Scip, Brn2 and Sox10 synergistically activate a reporter
through this enhancer (Ghislain and Charnay 2006; Kuhlbrodt et al. 1998a). While Oct6/Scip
and Brn2 are transiently upregulated during Schwann cell differentiation, Sox10 is expressed
at all developmental stages of the Schwann cell lineage (Jaegle et al. 2003; Kuhlbrodt et al.
1998b; Sim et al. 2002). Analysis of a hypomorphic Sox10 mutant mouse line (see below),
further confirms the involvement of Sox10 in regulation of Oct6/Scip.
The regulatory relationship between Sox10, Oct6, Brn2 and Krox20/Egr2 (Figure 1) resembles
that of a Feed-forward loop in which factor A (Sox10) activates factor B (Oct6/Scip) and
subsequently activates, in synergy with B, factor C (Krox20). Feed forward loops are common
regulatory motifs that provide temporal control and forward momentum in gene regulatory
networks (Shen-Orr et al. 2002;Swiers et al. 2006). That this regulatory circuit receives multiple
inputs is suggested by the observation that promyelinating Schwann cells in Lgi4 mutant
animals (Claw Paw; clp), which show a developmental delay similar to that observed in
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Oct6 mutant animals, express Oct6/Scip and Sox10, yet do not express Krox20/Egr2
(Bermingham et al. 2006;Bermingham et al. 2002;Darbas et al. 2004). As Lgi4 is a Schwann
cell expressed, secreted molecule it is conceivable that it modulates a signaling pathway that
triggers activation of Oct6/Scip or Sox10, for example through modifications such as
phosphorylation and acetylation, or the translation or stability of Krox20/Egr2 mRNA. It has
recently been shown that Oct6/Scip contains a nuclear export signal that allows the rapid
removal of Oct6/Scip from the nucleus (Baranek et al. 2005). It is however unlikely that this
mode of regulation plays a role in Lgi4 mutant Schwann cells as Oct6/Scip is mainly nuclear
in these cells (Darbas et al. 2004). Any post-translational mechanism operating on Oct6/Scip
should operate equally on Brn1 (Pou3f3) as it has been shown that Brn1 can fully substitute
for Oct6/Scip function in differentiating Schwann cells of mice in which the Brn1 gene was
knocked in the Oct6 locus, replacing the Oct6 gene (Friedrich et al. 2005).
In the regulatory motif described above, Oct6/Scip and Brn2 function as activators of gene
expression, in particular Krox20/Egr2. However, co-transfection experiments in primary rat
Schwannn cells have suggested that Oct6/Scip can also function as a repressor of major myelin
genes such as Myelin protein-zero (Mpz) and Myelin basic protein (Mbp) (Monuki et al.
1993; Monuki et al. 1990). It was suggested that Oct6/Scip represses reporter gene activation
through quenching of an activating complex on the Mpz and Mbp promoters. It remains unclear
what the physiological relevance of these findings is as analysis of Oct6/Scip mutant animals
did not support a repressive role for Oct6/Scip in promyelinating cells as in the absence of
Oct6/Scip, steady state levels of Mbp and Peripheral myelin protein-22 (Pmp22) mRNA, as
well as Mpz and Pmp22 protein levels, were strongly reduced (Jaegle et al. 1996).
Oct6/Scip regulation
Oct6/Scip was originally described as a POU domain factor that is repressed in primary rat
Schwann cell cultures but whose expression is upregulated with intermediate kinetics following
administration of cAMP (hence the name Suppressed cAMP inducible POU: Scip; (Monuki
et al. 1989). Activation of Protein kinase A (PKA), the main target of the second messenger
cAMP, in cultured Schwann cells results in upregulation of myelination associated genes,
suggesting a role for PKA in myelination (Morgan et al. 1991; Sobue et al. 1986). Indeed,
inhibition of PKA activity results in reduced myelination in DRG co-cultures (Howe and
McCarthy 2000). A major target of PKA signaling is the cAMP response element binding
protein or Crebp. Crebp is phosphorylated by PKA following cAMP administration to Schwann
cells but whether this has a direct effect on Oct6/Scip expression is unclear (Lee et al. 1999).
Another target of PKA is NFκB, a transcription factor involved in cell proliferation and
differentiation of a variety of cells (Zhong et al. 1998). NFκB is a transcription factor formed
by homo- or heterodimerization of 5 subunits (p65/RelB, RelA, c-rel, p52 and p50). Recently
it was shown that NFκB is required in Schwann cells for activation of Oct6/Scip and
myelination (Nickols et al. 2003). NFκB transcriptional activity can be regulated through
phosphorylation by PKA at Ser276 of p65 and PKA inhibition results in reduced myelin
formation in DRG co-cultures (Yoon et al. 2008). Although activated NFκB increases Oct6/
Scip protein levels in cultured Schwann cells, it did not affect Oct6/Scip mRNA levels
suggesting that NFκB regulates Oct6/Scip expression in Schwann cells at the
posttranscriptional level.
Oct6/Scip expression in vivo is controlled by axonal signals that include Type III Neuregulin1
(Leimeroth et al. 2002; Scherer et al. 1994; Taveggia et al. 2005). These signals converge on
the Oct6/Scip Schwann cell enhancer (SCE) element, located downstream of the gene, to
regulate every aspect of Oct6/Scip expression in Schwann cells (Ghazvini et al. 2002;
Mandemakers et al. 2000). Ongoing deletion analysis of this enhancer element in
differentiating Schwann cells has identified a 500 bp region that is required for activation both
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in cultured Schwann cells as well as in Schwann cells of transgenic mice (N.B. Jagalur, M.
Ghazvini and D.M. in prep). This element contains several Sox protein binding sites suggesting
a potential role for Sox proteins in Oct6/Scip regulation. Indeed, a hypomorphic allele of Sox10
that no longer homodimerizes does support Schwann cell development, but these Schwann
cells do not upregulate Oct6/Scip in late fetal life (Schreiner et al. 2007). Further analysis
should identify elements, in addition to Sox10 binding elements, that confer temporal control
of Oct6/Scip gene activation.
During normal nerve development, Oct6/Scip expression is rapidly extinguished in myelinating
Schwann cells. The mechanism through which Oct6/Scip expression is down regulated remains
unknown. We have previously speculated that Oct6/Scip is involved in its own downregulation
(Jaegle and Meijer 1998). Others have suggested that Krox20/Egr2 is involved in extinguishing
Oct6/Scip expression in myelinating cells as Krox20/Egr2 deleted Schwann cells fail to
downregulate Oct6/Scip (Zorick et al. 1999). This is very well possible as the Oct6/Scip
promoter region is in a CpG island and contains multiple Krox20/Egr2 binding sites. Krox20/
Egr2 has been shown to function as a transcriptional repressor through its interaction with the
Nab (NGFI-A/Egr binding) repressors (see below). However, evidence supporting a direct role
for Krox20/Egr2 in Oct6 downregulation is still lacking. Identification of the factors involved
in extinguishing Oct6/Scip expression is of importance as these factors could contribute to the
development of peripheral neuropathy. Indeed, forced expression of Oct6 in Schwann cells
beyond the early myelinating stages result in hypomyelination and axonal loss, emphasizing
the need for Oct6 downregulation during normal development (Ryu et al. 2007).
The role of Sox10 in myelinating Schwann cells
Although Sox10 expression is maintained in myelinating Schwann cells, the early embryonic
phenotype of the knockout mouse initially precluded testing a definitive role for Sox10 during
myelination by mature Schwann cells (Britsch et al. 2001). As noted above, Sox10 regulates
entry into the promyelinating stage through its role in Oct6/Scip and Krox20/Egr2 induction.
In addition, a number of lines of evidence indicate that Sox10 is required throughout the
myelination process. Several myelin genes have conserved Sox10 binding sites that appear to
be important for function (Bondurand et al. 2001; Denarier et al. 2005; Peirano et al. 2000),
and binding of Sox10 to these sites has been shown in myelinating sciatic nerve in vivo
(LeBlanc et al. 2007). Finally, identification of SOX10 mutants in a complex human syndrome
that includes peripheral myelin defects—PCWH: peripheral demyelinating neuropathy, central
dysmyelinating leukodystrophy, Waardenburg syndrome and Hirschsprung disease (Inoue et
al. 2004)—further highlights the importance of Sox10 in not only Schwann cell specification
but also initiation of myelination.
Initial characterization of Sox10 deficient mice revealed that it is required for embryonic
expression of Mpz and binds to several sites in the Mpz promoter (Peirano et al. 2000). Using
these target sites, a number of elegant structure/function studies of Sox10 have further
elucidated its mechanism of action. One unique feature of the E class of Sox factors is their
ability to bind DNA as either monomers or dimers. Dimer formation can increase apparent
affinity as shown by cooperative binding of a Sox10 dimer to two adjacent sites in an inverted
orientation (C/C’) in the Mpz promoter (Peirano and Wegner 2000). Another striking aspect
of Sox10 is its ability to induce DNA bending, and both Sox10 monomers and dimers can
induce bends of ~80° and 100°, respectively. The ultimate significance of the DNA bending
has yet to be elucidated (Schlierf et al. 2002), but it would be expected to dramatically change
the architecture of target loci, and facilitate interactions between target promoters and more
distal regulatory elements.
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A knock in of Sox8 into the Sox10 locus revealed that Sox8 could largely fulfill the role of
Sox10 in peripheral nerve development if expressed under the same developmental control
(Kellerer et al. 2006). Recent in vivo experiments have begun to test the role of protein domains
that are shared among the E class Sox factors. A domain N-terminal of the HMG class DNA-
binding domain has been shown to mediate Sox10 dimer formation (Peirano and Wegner
2000). As noted above, Sox10 mutant with a defective dimerization domain is able to sustain
early Schwann development, but resulting Schwann cells do not enter the promyelinating stage,
characterized by expression of Oct6/Scip. In contrast, a hypomorphic Sox10 allele with a
deletion of the K2 activation domain can drive Schwann cells to the promyelinating stage, but
fails to initiate myelination (Schreiner et al. 2007).
Sites of Krox20/Egr2 action and interactions with Sox10
The genes controlled by Krox20/Egr2 have been elucidated by expression analyses of knockout
mice (Le et al. 2005a; Topilko et al. 1994), and ectopic expression of Krox20/Egr2 in primary
Schwann cells (Nagarajan et al. 2001). These analyses highlighted not only major myelin genes
such as Mpz, Mbp, Pmp22, Connexin 32 (Cx32), and Myelin-associated glycoprotein (Mag),
but also identified several genes involved in the tremendous increase in lipid biosynthesis
during myelination, such as HMG CoA reductase (Leblanc et al. 2005) (see below). Many of
the Krox20/Egr2-regulated genes identified in these studies are also controlled by Sox10. One
of the first examples of this combinatorial regulation was provided by analysis of the promoter
of the Cx32 gene, which itself is a target of an X-linked form of CMT (CMTX). The promoter
for Cx32 contains binding sites for both Egr2 and Sox10 (Figure 3A), and transfection assays
showed synergistic activation of this promoter by the two factors. Furthermore, a promoter
mutation found in a patient with CMT interferes with binding of Sox10 (Bondurand et al.
2001). Another example was found in the analysis of the Schwann cell enhancer of the Mbp
gene (Farhadi et al. 2003; Forghani et al. 2001; Taveggia et al. 2004), which contains conserved
binding sites for Krox20/Egr2 and Sox10. Mutation of these sites results in diminished ability
of this enhancer to drive peripheral nerve expression in transgenic experiments (Denarier et
al. 2005). Other occurrences of a composite module consisting of conserved Krox20/Egr2 and
Sox10 sites have been recently defined in other myelin genes (Jones et al. 2008)
Although Mpz is the most highly expressed myelin gene, its control by Krox20/Egr2 initially
proved enigmatic since relatively minor effects on Mpz promoter function were observed
(Nagarajan et al. 2001; Peirano et al. 2000; Slutsky et al. 2003; Zorick et al. 1999). However,
a transgenic analysis of the Mpz locus had indicated that important control elements resided
downstream of the transcription start site (Feltri et al. 1999). Based on comparative genomic
analysis, we recently described a conserved element within the first intron of the Mpz gene
(LeBlanc et al. 2006), which contains binding sites for both Egr2 and Sox10 (Figure 3A).
Reporter assays showed that the isolated intron element responds to treatments that induce
endogenous Mpz expression in Schwann cells, and chromatin immunoprecipitation analysis in
cell lines and also myelinating sciatic nerve in vivo confirmed binding of both Egr2 and Sox10
to this conserved intron element. Interestingly, intron localization of myelin gene enhancers
may prove to be a common theme, since a similar analysis identified another intron-associated
enhancer for the Mag gene, with an Egr2 site located proximal to an inverted pair of Sox10
sites (Jang et al. 2006; LeBlanc et al. 2007). Altogether, accumulating evidence indicates that
enacting the myelination program in Schwann cells depends upon convergent regulation
exerted by the Sox10 specification factor and axon-dependent stimulation by Krox20/Egr2.
Notwithstanding, Sox10 appears to interact promiscuously with a variety of different factors
(Wissmuller et al. 2006), including Oct6/Scip and others (Ghislain and Charnay 2006;
Kuhlbrodt et al. 1998a). Another example uncovered in studies of the Mpz promoter is the
cooperation of Sox10 with the Zbp99 factor, which is induced by gp130-mediating signaling
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in Schwann cells (Slutsky et al. 2003). Overall, interactions of Sox10 with diverse partners
probably underly its ability to foster Schwann cell differentiation at many stages from neural
crest specification to myelination.
EGR2 Mutations in Human Peripheral Neuropathies
Several groups identified mutations in the human EGR2 gene associated with peripheral
myelinopathies, including Charcot-Marie-Tooth disease, as well as the more severe forms of
Dejerine-Sottas Syndrome and Congenital Hypomyelinating Neuropathy (Figure 3B).
Dominant neuropathy-associated mutations of EGR2 have been identified in all three zinc
fingers of the DNA-binding domain (Bellone et al. 1999; Mikesova et al. 2005; Pareyson et
al. 2000; Szigeti et al. 2007; Timmerman et al. 1999; Warner et al. 1998), and these mutations
generally impair or prevent DNA-binding (Musso et al. 2001; Musso et al. 2003; Warner et al.
1999). The underlying mechanisms by which dominant EGR2 mutants cause myelinopathies
have recently been investigated. One of the affected pathways involves cell cycle regulation,
based on observations that Krox20/Egr2 induces cell cycle arrest of Schwann cells by
antagonizing regulation of the JNK/c-jun pathway (see below, Parkinson et al. 2004). In
contrast, expression of a dominant negative mutant form of Krox20/Egr2 induces Schwann
cell proliferation through upregulation of cyclin D1 and reduction of the cyclin-dependent
kinase inhibitor, p27 (Arthur-Farraj et al. 2006).
The dominant Egr2 mutants interfere with activation of some endogenous target genes in
Schwann cells by wild type Egr2 (Arthur-Farraj et al. 2006; Nagarajan et al. 2001), with the
most striking effects observed on Mpz expression. Recent analysis of Mpz regulatory elements
indicated that Krox20/Egr2 activation of the intron element, but not the promoter, was sensitive
to expression of dominant neuropathy-associated Krox20/Egr2 mutants. Binding of Sox10 to
the Mpz intron element was required for the dominant negative effects, and expression of a
Krox20/Egr2 dominant mutant displaced Sox10 binding from the intron element. Overall, these
data are consistent with a model in which the dominant Egr2 mutants interfere with interactions
required for Egr2-dependent binding of Sox10 to the conserved intron element of Mpz (LeBlanc
et al. 2007). Cooperation between Krox20/Egr2 and Sox10 probably involves the recently
characterized interaction between their DNA-binding domains (Wissmuller et al. 2006),
although it appears that other domains are also involved.
Gene repression in the myelination process
Like most transcriptional regulators, the ultimate effect of Krox20/Egr2 on a given target gene
is determined by its association with coactivators and corepressors. Krox20/Egr2 has been
linked with the p300 Histone acetylase and HCF1 cofactor (Luciano and Wilson 2003), which
has been identified as a component of complexes containing the Mll histone H3K4 methylases
(Yokoyama et al. 2004). However, screening for Krox20/Egr2-interacting proteins has
identified mostly co-repressors such as the Nab co-repressors, which repress Egr-mediated
transcription (Russo et al. 1995; Svaren et al. 1996; Svaren et al. 1998). Other interacting co-
repressor proteins include the Piasxβ Sumo ligase (Garcia-Dominguez et al. 2006), and the
Ddx20 member of the RNA helicase family (Gillian and Svaren 2004), although the functions
of these in Schwann cell differentiation have not been explored.
Of these cofactors, the most extensive evidence supports an integral role of the Nab co-
repressors in regulation of myelin gene expression. One of the EGR2 mutations associated with
a very severe congenital hypomyelinating neuropathy (I268N, Warner et al. 1998) prevents
binding of EGR2 to NAB proteins (Figure 3B, Warner et al. 1999). The importance of Nab co-
repressors to the regulation of peripheral nerve myelination by Egr2 was confirmed by the
demonstration that a double knockout of the Nab1/Nab2 genes results in a phenotype very
similar to that of Krox20/Egr2 deficient mice: early lethality and peripheral neuropathy
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resulting from arrested myelination (Le et al. 2005b). Although Nab co-repressors may interact
with other transcriptional regulators, a recent knock in analysis of a Nab-resistant allele of
Egr2 confirmed the importance of the interaction of Nab proteins with Egr2/Krox20
(Desmazieres et al. 2008). Nab proteins are active repressors when recruited to a transcriptional
template (Svaren et al. 1998; Swirnoff et al. 1998), and recent progress has elucidated the
mechanism by which Nab proteins repress transcription. Deletion analysis of Nab2 showed
that it had two independent repression domains, one of which was found to interact with the
Chromodomain Helicase DNA-binding 4 (CHD4) protein (Srinivasan et al. 2006). CHD4 is
an integral subunit of the NuRD (nucleosome remodeling and deacetylase) chromatin-
remodeling complex. Repression by this complex involves both histone deacetylation and
nucleosome mobilization mechanisms (reviewed in Bowen et al. 2004; Feng and Zhang
2003) and CHD4 is highly expressed in peripheral nerve.
Analysis of Nab expression initially suggested that Nab proteins serve as feedback inhibitors
of Egr2. Indeed, characterization of the Nab1 and Nab2 promoters identified multiple Egr
binding sites (Le et al. 2005b), and recent analysis indicates that Nab co-repressors are induced
by Egr2 and other neuregulin-dependent transcription factors (Srinivasan et al. 2007).
However, a negative feedback model would predict that loss of Nab1/Nab2 would cause
overexpression of myelin genes. A striking aspect of this knockout is the notable absence of
myelin gene overexpression (Le et al. 2005b), and similar results were obtained with knock in
of a Nab-resistant allele of Krox20/Egr2 (Desmazieres et al. 2008). Overall, the data indicate
that Nab proteins do not play a negative feedback role in activation of major myelin genes by
Krox20/Egr2, and may indicate that Nab proteins can act as coactivators in certain contexts.
Recent studies have uncovered a number of genes that are apparently repressed by Krox20/
Egr2 (directly or indirectly) in peripheral nerve development. In addition to the proposed
repression of Oct6/Scip expression (discussed above, Zorick et al. 1999) Krox20/Egr2
expression in Schwann cells was also found to downregulate the L1 marker of immature
Schwann cells (Parkinson et al. 2003) and antagonize expression and activity of c-jun
(Parkinson et al. 2008; Parkinson et al. 2004). Subsequent microarray analysis of Krox20/Egr2
hypomorphic mice showed that Egr2 downregulated expression of the Sox2 transcription factor
(Le et al. 2005a), which is generally associated with pluripotency and maintenance of a stem
cell phenotype in a variety of cell lineages. Moreover, expression of Krox20/Egr2 in primary
Schwann cells represses Sox2 expression (Parkinson et al. 2008), and induction of Sox2 and
Oct6/Scip was also observed after induced deletion of Krox20/Egr2 in mature Schwann cells
(Decker et al. 2006). Repression of at least some of these genes requires interaction of Nab
proteins with Krox20/Egr2, as Oct6/Scip, Sox2, Id2 and Id4 are upregulated in the absence of
Nab function (Desmazieres et al. 2008; Le et al. 2005b). It should be noted that expression
profiling alone does not prove a direct role for Nab-dependent repression of such genes by
Krox20/Egr2, and there is so far no evidence of direct repression of either Sox2 or Oct6/Scip.
However, analysis of Nab-regulated genes has recently provided evidence of direct repression
of some target genes, including Id2 and Id4, by Krox20/Egr2 in vivo (Mager et al. 2008).
Krox20/Egr2 and its close relatives
Krox20/Egr2 is a member of a small family of early growth response (Egr) genes that includes
Egr1 and Egr3. Krox20/Egr2 is co-expressed with the highly related Egr1 factor in Schwann
cells at the onset of myelination (P1). In contrast by one month of age, Krox20/Egr2 is
exclusively expressed in myelinating Schwann cells, whereas Egr1 is confined to
nonmyelinating Schwann cells (Topilko et al. 1997). Conversely, after nerve injury, Krox20/
Egr2 is downregulated and Egr1 becomes induced. Despite the intriguing expression pattern
of Egr1, no deficiency in peripheral nerve myelination has been noted in two independent
knockout lines (Lee et al. 1996; Topilko et al. 1998). It had been suggested that Egr1 could
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regulate expression of the p75 neurotrophin receptor (Nikam et al. 1995), which is expressed
by nonmyelinating Schwann cells and is required for effective myelination (Cosgaya et al.
2002). Although p75 expression is not diminished in the Egr1 knockout, Egr3 is also co-
expressed in p75-expressing Schwann cells in sciatic nerve. Moreover, a double knockout of
Egr1 and Egr3 exhibits lower p75 expression and thinner myelin sheaths comparable to the
phenotype caused by p75 deficiency (Gao et al. 2007). Since Egr1 and Egr3 share many
properties with Krox20/Egr2, including the ability to interact with NAB corepressors (Sevetson
et al. 2000), an important question is how Egr2’s role is distinct from, or overlaps with, the
function of Egr1 and Egr3.
Transcriptional regulation of demyelination
If specific transcriptional programs must be repressed to allow myelination, a corollary idea is
that demyelination associated with nerve injury (or certain types of hereditary peripheral
neuropathy) is also coordinated by a specific transcriptional program. Pathways involved in
nonmyelinating Schwann cell formation/maintenance have been reviewed recently (Jessen and
Mirsky 2005), and one of the major pathways that has emerged involves the c-jun activator,
which had previously been shown to be involved in Schwann cell proliferation (Parkinson et
al. 2004). These studies have described a mutually antagonistic relationship between Krox20/
Egr2 and c-jun that regulates the transitions between nonmyelinating and myelinating Schwann
cells (Figure 1, Parkinson et al. 2008) and have provided a mechanistic basis for previous
observations that Schwann cells in Krox20/Egr2 deficient mice not only fail to myelinate, but
also exhibit higher levels of proliferation and apoptosis (Le et al. 2005a; Topilko et al. 1994;
Zorick et al. 1999). Moreover, c-jun is also able to antagonize myelin gene expression
independent of its cell cycle effects (Parkinson et al. 2008).
Another variation on this theme was recently presented in an analysis of a mouse model of
CMT1B, which is caused by a gain-of-function mutant of Mpz. Expression of this mutant was
shown to provoke a canonical unfolded protein response (UPR), characterized by induction of
the Chop transcription factor and Bip chaperone (Pennuto et al. 2008). Interestingly, the same
Mpz mutant in a Chop null background exhibited reduced demyelination, indicating that the
unfolded protein response plays an important role in demyelination caused by this mutant.
Although Chop has been implicated in promoting apoptosis in some systems, its activation in
Schwann cells apparently causes demyelination in the absence of apoptosis. These findings
indicate that targeting the activity of Chop or other UPR mediators could be an attractive target
for treatment for human peripheral neuropathies, and it will be important to determine if Chop
activation occurs as a consequence of other myelin gene mutations.
Coordination of Lipid Synthesis with Myelination
An important aspect of myelination is the coordination of myelin gene induction with the high
level of lipid synthesis required for production of multiple layers of cholesterol-rich membrane.
Indeed, a striking aspect of myelination is that most of the cholesterol required is synthesized
locally rather than being absorbed from the circulation (Jurevics and Morell 1994). Gene
expression profiling revealed coordinate regulation of various lipid biosynthesis genes during
myelination and after nerve injury (Nagarajan et al. 2002; Verheijen et al. 2003). The regulatory
element binding proteins (Srebp) are network regulators of genes involved in synthesis of fatty
acids and cholesterol and are also expressed in Schwann cells during the myelination process,
apparently regulating lipid biosynthetic genes (Verheijen et al. 2003). Preliminary observations
in mice carrying a Schwann cell specific deletion of Scap (Srebp activation depends on Scap
function) indicate that the function of Srebps is required for proper myelination (M.H.G.
Verheijen, personal communication). Srebp controlled gene expression appears to converge
with Krox20/Egr2 regulation on several target gene promoters, including that of the HMG CoA
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reductase gene, encoding a protein that represents the rate-limiting step in cholesterol
biosynthesis (Leblanc et al. 2005). Accordingly, ectopic expression of Egr2 in primary
Schwann cells activated several known Srebp target genes (Nagarajan et al. 2001). Srebp-
dependent gene regulation probably plays a role beyond development, since disregulation of
insulin-regulated Srebp1c expression in Schwann cells might play a role in diabetic neuropathy
(de Preux et al. 2007).
Transcription-based therapies for human peripheral myelinopathies
Most inherited peripheral myelinopathies are caused by altered gene dosage of myelin genes,
i.e. Pmp22 and Mpz (Saifi et al. 2003; Szigeti et al. 2006; Wrabetz et al. 2006). Therefore,
transcription-based therapies that effect a relatively subtle (<2-fold) change in expression levels
could be a very fruitful mode of treatment for these very common diseases. One active area of
investigation is that of steroid receptors, such as the progesterone and glucocorticoid receptors,
which play an important role in regulation of myelination. Recent proof-of-principle studies
using progesterone antagonists to reduce Pmp22 expression in a rat model of CMT1A have
shown beneficial effects (Sereda et al. 2003). Although progesterone has been shown to
enhance myelination and elevate expression of Pmp22 and other myelin genes (Koenig et al.
1995; Melcangi et al. 1999), specific binding sites for the progesterone receptor have not been
defined in myelin genes. Recent studies indicate that progesterone’s effects may be mediated
by stimulated synthesis of Krox20/Egr2 and Sox10 in Schwann cells (Guennoun et al. 2001;
Magnaghi et al. 2007), which would be consistent with downregulation of Mpz levels in rat
sciatic nerve (Melcangi et al. 2003) after administration of a glucocorticoid/progesterone
antagonist (mifepristone).
Concluding remarks
Although substantial progress has been made in identifying the pathways underlying
commitment to myelination, considerable challenges remain in defining the mechanisms by
which myelin gene regulation is controlled. First of all, the signal transduction pathways by
which axon-dependent events give rise to nuclear activation of gene networks remain largely
unexplored. Recent elegant work has defined important requirements for Type III neuregulin
signaling and activation of PI3 kinase pathways to control the initiation and extent of
myelination (Michailov et al. 2004; Taveggia et al. 2005). However, more work will be required
to connect axon-dependent signaling pathways to transcription factors that direct myelin gene
expression. Second, the interactions between Sox10, Krox20/Egr2, and Oct6/Scip represent
probably only a small proportion of the combinatorial interactions that induce and repress gene
expression during myelination, and future work promises to elucidate other such examples.
Third, Oct6/Scip and Sox2 are prototypes of regulators that are downregulated during
myelination, and the recent progress in studies of c-jun and Chop function have opened exciting
therapeutic avenues by which demyelination (and subsequent nerve damage) could be
prevented. However, the molecular targets of these factors that trigger demyelination (or a
nonmyelinating phenotype) have yet to be defined. Finally, the specific roles of chromatin
remodeling complexes and histone modifications have not yet emerged from studies of myelin
gene regulation, and mechanistic analysis of factors directing myelination have not yet
uncovered how they alter the chromatin configuration of their target loci.
Acknowledgments
Work in the laboratory of JS is supported by grants from National Institutes of Health (HD41590), Muscular Dystrophy
Association, and the Charcot-Marie-Tooth Association. Work in the laboratory of DM is supported by grants from
NWO (Vici 918.66.616), the BSIK program of the Dutch Government (BSIK 03038, Stem Cells in Development and
Disease) and the European Union (FP7 NGIDD).
Svaren and Meijer Page 9
Glia. Author manuscript; available in PMC 2010 August 31.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
References
Arthur-Farraj P, Mirsky R, Parkinson DB, Jessen KR. A double point mutation in the DNA-binding
region of Egr2 switches its function from inhibition to induction of proliferation: A potential
contribution to the development of congenital hypomyelinating neuropathy. Neurobiol Dis 2006;24
(1):159–169. [PubMed: 16872830]
Baranek C, Sock E, Wegner M. The POU protein Oct-6 is a nucleocytoplasmic shuttling protein. Nucleic
Acids Res 2005;33(19):6277–6286. [PubMed: 16260476]
Bellone E, Di Maria E, Soriani S, Varese A, Doria LL, Ajmar F, Mandich P. A novel mutation (D305V)
in the early growth response 2 gene is associated with severe Charcot-Marie-Tooth type 1 disease.
Hum Mutat 1999;14(4):353–354. [PubMed: 10502832]
Bermingham JR Jr, Scherer SS, O'Connell S, Arroyo E, Kalla KA, Powell FL, Rosenfeld MG. Tst-1/
Oct-6/SCIP regulates a unique step in peripheral myelination and is required for normal respiration.
Genes Dev 1996;10(14):1751–1762. [PubMed: 8698235]
Bermingham JR Jr, Shearin H, Pennington J, O'Moore J, Jaegle M, Driegen S, van Zon A, Darbas A,
Ozkaynak E, Ryu EJ, et al. The claw paw mutation reveals a role for Lgi4 in peripheral nerve
development. Nat Neurosci 2006;9(1):76–84. [PubMed: 16341215]
Bermingham JR Jr, Shumas S, Whisenhunt T, Sirkowski EE, O'Connell S, Scherer SS, Rosenfeld MG.
Identification of genes that are downregulated in the absence of the POU domain transcription factor
pou3f1 (Oct-6, Tst-1, SCIP) in sciatic nerve. J Neurosci 2002;22(23):10217–10231. [PubMed:
12451123]
Bondurand N, Girard M, Pingault V, Lemort N, Dubourg O, Goossens M. Human Connexin 32, a gap
junction protein altered in the X-linked form of Charcot-Marie-Tooth disease, is directly regulated by
the transcription factor SOX10. Hum Mol Genet 2001;10(24):2783–2795. [PubMed: 11734543]
Bowen NJ, Fujita N, Kajita M, Wade PA. Mi-2/NuRD: multiple complexes for many purposes. Biochim
Biophys Acta 2004;1677(1–3):52–57. [PubMed: 15020045]
Britsch S, Goerich DE, Riethmacher D, Peirano RI, Rossner M, Nave KA, Birchmeier C, Wegner M.
The transcription factor Sox10 is a key regulator of peripheral glial development. Genes Dev 2001;15
(1):66–78. [PubMed: 11156606]
Cosgaya JM, Chan JR, Shooter EM. The neurotrophin receptor p75NTR as a positive modulator of
myelination. Science 2002;298(5596):1245–1248. [PubMed: 12424382]
Darbas A, Jaegle M, Walbeehm E, van den Burg H, Driegen S, Broos L, Uyl M, Visser P, Grosveld F,
Meijer D. Cell autonomy of the mouse claw paw mutation. Dev Biol 2004;272(2):470–482. [PubMed:
15282162]
de Preux AS, Goosen K, Zhang W, Sima AA, Shimano H, Ouwens DM, Diamant M, Hillebrands JL,
Rozing J, Lemke G, et al. SREBP-1c expression in Schwann cells is affected by diabetes and
nutritional status. Mol Cell Neurosci 2007;35(4):525–534. [PubMed: 17632011]
Decker L, Desmarquet-Trin-Dinh C, Taillebourg E, Ghislain J, Vallat JM, Charnay P. Peripheral myelin
maintenance is a dynamic process requiring constant Krox20 expression. J Neurosci 2006;26(38):
9771–9779. [PubMed: 16988048]
Denarier E, Forghani R, Farhadi HF, Dib S, Dionne N, Friedman HC, Lepage P, Hudson TJ, Drouin R,
Peterson A. Functional organization of a Schwann cell enhancer. J Neurosci 2005;25(48):11210–
11217. [PubMed: 16319321]
Desmazieres A, Decker L, Vallat JM, Charnay P, Gilardi-Hebenstreit P. Disruption of Krox20-Nab
interaction in the mouse leads to peripheral neuropathy with biphasic evolution. J Neurosci 2008;28
(23):5891–5900. [PubMed: 18524893]
Farhadi HF, Lepage P, Forghani R, Friedman HC, Orfali W, Jasmin L, Miller W, Hudson TJ, Peterson
AC. A combinatorial network of evolutionarily conserved myelin basic protein regulatory sequences
confers distinct glial-specific phenotypes. J Neurosci 2003;23(32):10214–10223. [PubMed:
14614079]
Feltri ML, D'Antonio M, Quattrini A, Numerato R, Arona M, Previtali S, Chiu SY, Messing A, Wrabetz
L. A novel P0 glycoprotein transgene activates expression of lacZ in myelin-forming Schwann cells.
Eur J Neurosci 1999;11(5):1577–1586. [PubMed: 10215910]
Svaren and Meijer Page 10
Glia. Author manuscript; available in PMC 2010 August 31.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Feng Q, Zhang Y. The NuRD complex: linking histone modification to nucleosome remodeling. Curr
Top Microbiol Immunol 2003;274:269–290. [PubMed: 12596911]
Finzsch M, Stolt CC, Lommes P, Wegner M. Sox9 and Sox10 influence survival and migration of
oligodendrocyte precursors in the spinal cord by regulating PDGF receptor alpha expression.
Development 2008;135(4):637–646. [PubMed: 18184726]
Forghani R, Garofalo L, Foran DR, Farhadi HF, Lepage P, Hudson TJ, Tretjakoff I, Valera P, Peterson
A. A distal upstream enhancer from the myelin basic protein gene regulates expression in myelin-
forming schwann cells. J Neurosci 2001;21(11):3780–3787. [PubMed: 11356866]
Friedrich RP, Schlierf B, Tamm ER, Bosl MR, Wegner M. The class III POU domain protein Brn-1 can
fully replace the related Oct-6 during schwann cell development and myelination. Mol Cell Biol
2005;25(5):1821–1829. [PubMed: 15713637]
Gao X, Daugherty RL, Tourtellotte WG. Regulation of low affinity neurotrophin receptor (p75(NTR))
by early growth response (Egr) transcriptional regulators. Mol Cell Neurosci 2007;36(4):501–514.
[PubMed: 17916431]
Garcia-Dominguez M, Gilardi-Hebenstreit P, Charnay P. PIASxbeta acts as an activator of Hoxb1 and
is antagonized by Krox20 during hindbrain segmentation. Embo J 2006;25(11):2432–2442.
[PubMed: 16675951]
Ghazvini M, Mandemakers W, Jaegle M, Piirsoo M, Driegen S, Koutsourakis M, Smit X, Grosveld F,
Meijer D. A cell type-specific allele of the POU gene Oct-6 reveals Schwann cell autonomous
function in nerve development and regeneration. Embo J 2002;21(17):4612–4620. [PubMed:
12198163]
Ghislain J, Charnay P. Control of myelination in Schwann cells: a Krox20 cis-regulatory element
integrates Oct6, Brn2 and Sox10 activities. EMBO Rep 2006;7(1):52–58. [PubMed: 16311519]
Ghislain J, Desmarquet-Trin-Dinh C, Jaegle M, Meijer D, Charnay P, Frain M. Characterisation of cis-
acting sequences reveals a biphasic, axon-dependent regulation of Krox20 during Schwann cell
development. Development 2002;129(1):155–166. [PubMed: 11782409]
Gillian AL, Svaren J. The Ddx20/DP103 dead box protein represses transcriptional activation by Egr2/
Krox-20. J Biol Chem 2004;279(10):9056–9063. [PubMed: 14699164]
Guennoun R, Benmessahel Y, Delespierre B, Gouezou M, Rajkowski KM, Baulieu EE, Schumacher M.
Progesterone stimulates Krox-20 gene expression in Schwann cells. Brain Res Mol Brain Res
2001;90(1):75–82. [PubMed: 11376858]
Howe DG, McCarthy KD. Retroviral inhibition of cAMP-dependent protein kinase inhibits myelination
but not Schwann cell mitosis stimulated by interaction with neurons. J Neurosci 2000;20(10):3513–
3521. [PubMed: 10804191]
Inoue K, Khajavi M, Ohyama T, Hirabayashi S, Wilson J, Reggin JD, Mancias P, Butler IJ, Wilkinson
MF, Wegner M, et al. Molecular mechanism for distinct neurological phenotypes conveyed by allelic
truncating mutations. Nat Genet 2004;36(4):361–369. [PubMed: 15004559]
Jaegle M, Ghazvini M, Mandemakers W, Piirsoo M, Driegen S, Levavasseur F, Raghoenath S, Grosveld
F, Meijer D. The POU proteins Brn-2 and Oct-6 share important functions in Schwann cell
development. Genes Dev 2003;17(11):1380–1391. [PubMed: 12782656]
Jaegle M, Mandemakers W, Broos L, Zwart R, Karis A, Visser P, Grosveld F, Meijer D. The POU factor
Oct-6 and Schwann cell differentiation. Science 1996;273(5274):507–510. [PubMed: 8662541]
Jaegle M, Meijer D. Role of Oct-6 in Schwann cell differentiation. Microsc Res Tech 1998;41(5):372–
378. [PubMed: 9672420]
Jang SW, LeBlanc SE, Roopra A, Wrabetz L, Svaren J. In vivo detection of Egr2 binding to target genes
during peripheral nerve myelination. J Neurochem 2006;98(5):1678–1687. [PubMed: 16923174]
Jessen KR, Mirsky R. The origin and development of glial cells in peripheral nerves. Nat Rev Neurosci
2005;6(9):671–682. [PubMed: 16136171]
Jones EA, Jang S-W, Mager GM, Chang L-W, Srinivasan R, Gokey NG, Ward RM, Nagarajan R, Svaren
J. Interactions of Sox10 and Egr2 in myelin gene regulation. Neuron Glia Biology 2007;3(04):377–
387. [PubMed: 18634568]
Jurevics HA, Morell P. Sources of cholesterol for kidney and nerve during development. J Lipid Res
1994;35(1):112–120. [PubMed: 8138712]
Svaren and Meijer Page 11
Glia. Author manuscript; available in PMC 2010 August 31.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Kellerer S, Schreiner S, Stolt CC, Scholz S, Bosl MR, Wegner M. Replacement of the Sox10 transcription
factor by Sox8 reveals incomplete functional equivalence. Development 2006;133(15):2875–2886.
[PubMed: 16790476]
Koenig HL, Schumacher M, Ferzaz B, Thi AN, Ressouches A, Guennoun R, Jung-Testas I, Robel P,
Akwa Y, Baulieu EE. Progesterone synthesis and myelin formation by Schwann cells. Science
1995;268(5216):1500–1503. [PubMed: 7770777]
Kuhlbrodt K, Herbarth B, Sock E, Enderich J, Hermans-Borgmeyer I, Wegner M. Cooperative function
of POU proteins and SOX proteins in glial cells. J Biol Chem 1998a;273(26):16050–16057.
[PubMed: 9632656]
Kuhlbrodt K, Herbarth B, Sock E, Hermans-Borgmeyer I, Wegner M. Sox10, a novel transcriptional
modulator in glial cells. J Neurosci 1998b;18(1):237–250. [PubMed: 9412504]
Le N, Nagarajan R, Wang JY, Araki T, Schmidt RE, Milbrandt J. Analysis of congenital hypomyelinating
Egr2Lo/Lo nerves identifies Sox2 as an inhibitor of Schwann cell differentiation and myelination.
Proc Natl Acad Sci U S A 2005a;102(7):2596–2601. [PubMed: 15695336]
Le N, Nagarajan R, Wang JY, Svaren J, LaPash C, Araki T, Schmidt RE, Milbrandt J. Nab proteins are
essential for peripheral nervous system myelination. Nat Neurosci 2005b;8(7):932–940. [PubMed:
16136673]
LeBlanc SE, Jang SW, Ward RM, Wrabetz L, Svaren J. Direct regulation of myelin protein zero
expression by the Egr2 transactivator. J Biol Chem 2006;281(9):5453–5460. [PubMed: 16373334]
Leblanc SE, Srinivasan R, Ferri C, Mager GM, Gillian-Daniel AL, Wrabetz L, Svaren J. Regulation of
cholesterol/lipid biosynthetic genes by Egr2/Krox20 during peripheral nerve myelination. J
Neurochem 2005;93(3):737–748. [PubMed: 15836632]
LeBlanc SE, Ward RM, Svaren J. Neuropathy-associated Egr2 mutants disrupt cooperative activation of
myelin protein zero by Egr2 and Sox10. Mol Cell Biol 2007;27(9):3521–3529. [PubMed: 17325040]
Lee MM, Badache A, DeVries GH. Phosphorylation of CREB in axon-induced Schwann cell
proliferation. J Neurosci Res 1999;55(6):702–712. [PubMed: 10220111]
Lee MM, Sato-Bigbee C, De Vries GH. Schwann cells stimulated by axolemma-enriched fractions
express cyclic AMP responsive element binding protein. J Neurosci Res 1996;46(2):204–210.
[PubMed: 8915897]
Leimeroth R, Lobsiger C, Lussi A, Taylor V, Suter U, Sommer L. Membrane-bound neuregulin1 type
III actively promotes Schwann cell differentiation of multipotent Progenitor cells. Dev Biol 2002;246
(2):245–258. [PubMed: 12051814]
Luciano RL, Wilson AC. HCF-1 functions as a coactivator for the zinc finger protein Krox20. J Biol
Chem 2003;278(51):51116–51124. [PubMed: 14532282]
Mager GM, Ward RM, Srinivasan R, Jang SW, Wrabetz L, Svaren J. Active Gene Repression by the
Egr2-NAB Complex during Peripheral Nerve Myelination. J Biol Chem 2008;283(26):18187–
18197. [PubMed: 18456662]
Magnaghi V, Ballabio M, Roglio I, Melcangi RC. Progesterone derivatives increase expression of
Krox-20 and Sox-10 in rat Schwann cells. J Mol Neurosci 2007;31(2):149–157. [PubMed: 17478888]
Mandemakers W, Zwart R, Jaegle M, Walbeehm E, Visser P, Grosveld F, Meijer D. A distal Schwann
cell-specific enhancer mediates axonal regulation of the Oct-6 transcription factor during peripheral
nerve development and regeneration. Embo J 2000;19(12):2992–3003. [PubMed: 10856243]
Melcangi RC, Azcoitia I, Ballabio M, Cavarretta I, Gonzalez LC, Leonelli E, Magnaghi V, Veiga S,
Garcia-Segura LM. Neuroactive steroids influence peripheral myelination: a promising opportunity
for preventing or treating age-dependent dysfunctions of peripheral nerves. Prog Neurobiol 2003;71
(1):57–66. [PubMed: 14611868]
Melcangi RC, Magnaghi V, Cavarretta I, Zucchi I, Bovolin P, D'Urso D, Martini L. Progesterone
derivatives are able to influence peripheral myelin protein 22 and P0 gene expression: possible
mechanisms of action. J Neurosci Res 1999;56(4):349–357. [PubMed: 10340743]
Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birchmeier C, Role L, Lai C, Schwab
MH, Nave KA. Axonal neuregulin-1 regulates myelin sheath thickness. Science 2004;304(5671):
700–703. [PubMed: 15044753]
Svaren and Meijer Page 12
Glia. Author manuscript; available in PMC 2010 August 31.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Mikesova E, Huhne K, Rautenstrauss B, Mazanec R, Barankova L, Vyhnalek M, Horacek O, Seeman P.
Novel EGR2 mutation R359Q is associated with CMT type 1 and progressive scoliosis. Neuromuscul
Disord 2005;15(11):764–767. [PubMed: 16198564]
Monuki ES, Kuhn R, Lemke G. Repression of the myelin P0 gene by the POU transcription factor SCIP.
Mech Dev 1993;42(1–2):15–32. [PubMed: 7690239]
Monuki ES, Kuhn R, Weinmaster G, Trapp BD, Lemke G. Expression and activity of the POU
transcription factor SCIP. Science 1990;249(4974):1300–1303. [PubMed: 1975954]
Monuki ES, Weinmaster G, Kuhn R, Lemke G. SCIP: a glial POU domain gene regulated by cyclic AMP.
Neuron 1989;3(6):783–793. [PubMed: 2561978]
Morgan L, Jessen KR, Mirsky R. The effects of cAMP on differentiation of cultured Schwann cells:
progression from an early phenotype (04+) to a myelin phenotype (P0+, GFAP-, N-CAM-, NGF-
receptor-) depends on growth inhibition. J Cell Biol 1991;112(3):457–467. [PubMed: 1704008]
Musso M, Balestra P, Bellone E, Cassandrini D, Di Maria E, Doria LL, Grandis M, Mancardi GL,
Schenone A, Levi G, et al. The D355V mutation decreases EGR2 binding to an element within the
Cx32 promoter. Neurobiol Dis 2001;8(4):700–706. [PubMed: 11493034]
Musso M, Balestra P, Taroni F, Bellone E, Mandich P. Different consequences of EGR2 mutants on the
transactivation of human Cx32 promoter. Neurobiol Dis 2003;12(1):89–95. [PubMed: 12609493]
Nagarajan R, Le N, Mahoney H, Araki T, Milbrandt J. Deciphering peripheral nerve myelination by using
Schwann cell expression profiling. Proc Natl Acad Sci U S A 2002;99(13):8998–9003. [PubMed:
12084938]
Nagarajan R, Svaren J, Le N, Araki T, Watson M, Milbrandt J. EGR2 mutations in inherited neuropathies
dominant-negatively inhibit myelin gene expression. Neuron 2001;30(2):355–368. [PubMed:
11394999]
Nickols JC, Valentine W, Kanwal S, Carter BD. Activation of the transcription factor NF-kappaB in
Schwann cells is required for peripheral myelin formation. Nat Neurosci 2003;6(2):161–167.
[PubMed: 12514737]
Nikam SS, Tennekoon GI, Christy BA, Yoshino JE, Rutkowski JL. The zinc finger transcription factor
Zif268/Egr-1 is essential for Schwann cell expression of the p75 NGF receptor. Mol Cell Neurosci
1995;6(4):337–348. [PubMed: 8846003]
Pareyson D, Taroni F, Botti S, Morbin M, Baratta S, Lauria G, Ciano C, Sghirlanzoni A. Cranial nerve
involvement in CMT disease type 1 due to early growth response 2 gene mutation. Neurology 2000;54
(8):1696–1698. [PubMed: 10762521]
Parkinson DB, Bhaskaran A, Arthur-Farraj P, Noon L, Woodhoo A, Lloyd AC, Feltri ML, Wrabetz L,
Behrens A, Mirsky R, et al. c-Jun is a negative regulator of myelination. J Cell. Biol 2008;181:625–
637. [PubMed: 18490512]
Parkinson DB, Bhaskaran A, Droggiti A, Dickinson S, D'Antonio M, Mirsky R, Jessen KR. Krox-20
inhibits Jun-NH2-terminal kinase/c-Jun to control Schwann cell proliferation and death. J Cell Biol
2004;164(3):385–394. [PubMed: 14757751]
Parkinson DB, Dickinson S, Bhaskaran A, Kinsella MT, Brophy PJ, Sherman DL, Sharghi-Namini S,
Duran Alonso MB, Mirsky R, Jessen KR. Regulation of the myelin gene periaxin provides evidence
for Krox-20-independent myelin-related signalling in Schwann cells. Mol Cell Neurosci 2003;23(1):
13–27. [PubMed: 12799134]
Peirano RI, Goerich DE, Riethmacher D, Wegner M. Protein zero gene expression is regulated by the
glial transcription factor Sox10. Mol Cell Biol 2000;20(9):3198–3209. [PubMed: 10757804]
Peirano RI, Wegner M. The glial transcription factor Sox10 binds to DNA both as monomer and dimer
with different functional consequences. Nucleic Acids Res 2000;28(16):3047–3055. [PubMed:
10931919]
Pennuto M, Tinelli E, Malaguti M, Del Carro U, D'Antonio M, Ron D, Quattrini A, Feltri ML, Wrabetz
L. Ablation of the UPR-mediator CHOP restores motor function and reduces demyelination in
Charcot-Marie-Tooth 1B mice. Neuron 2008;57(3):393–405. [PubMed: 18255032]
Russo MW, Sevetson BR, Milbrandt J. Identification of NAB1, a repressor of NGFI-A- and Krox20-
mediated transcription. Proc Natl Acad Sci U S A 1995;92(15):6873–6877. [PubMed: 7624335]
Svaren and Meijer Page 13
Glia. Author manuscript; available in PMC 2010 August 31.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Ryu EJ, Wang JY, Le N, Baloh RH, Gustin JA, Schmidt RE, Milbrandt J. Misexpression of Pou3f1 results
in peripheral nerve hypomyelination and axonal loss. J Neurosci 2007;27(43):11552–11559.
[PubMed: 17959798]
Saifi GM, Szigeti K, Snipes GJ, Garcia CA, Lupski JR. Molecular mechanisms, diagnosis, and rational
approaches to management of and therapy for Charcot-Marie-Tooth disease and related peripheral
neuropathies. J Investig Med 2003;51(5):261–283.
Scherer SS, Wang DY, Kuhn R, Lemke G, Wrabetz L, Kamholz J. Axons regulate Schwann cell
expression of the POU transcription factor SCIP. J Neurosci 1994;14(4):1930–1942. [PubMed:
8158248]
Schlierf B, Ludwig A, Klenovsek K, Wegner M. Cooperative binding of Sox10 to DNA: requirements
and consequences. Nucleic Acids Res 2002;30(24):5509–5516. [PubMed: 12490719]
Schreiner S, Cossais F, Fischer K, Scholz S, Bosl MR, Holtmann B, Sendtner M, Wegner M.
Hypomorphic Sox10 alleles reveal novel protein functions and unravel developmental differences
in glial lineages. Development 2007;134(18):3271–3281. [PubMed: 17699610]
Sereda MW, Meyer zu Horste G, Suter U, Uzma N, Nave KA. Therapeutic administration of progesterone
antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 2003;9(12):1533–1537.
[PubMed: 14608378]
Sevetson BR, Svaren J, Milbrandt J. A novel activation function for NAB proteins in EGR-dependent
transcription of the luteinizing hormone beta gene. J Biol Chem 2000;275(13):9749–9757. [PubMed:
10734128]
Shen-Orr SS, Milo R, Mangan S, Alon U. Network motifs in the transcriptional regulation network of
Escherichia coli. Nat Genet 2002;31(1):64–68. [PubMed: 11967538]
Sim FJ, Zhao C, Li WW, Lakatos A, Franklin RJ. Expression of the POU-domain transcription factors
SCIP/Oct-6 and Brn-2 is associated with Schwann cell but not oligodendrocyte remyelination of the
CNS. Mol Cell Neurosci 2002;20(4):669–682. [PubMed: 12213447]
Slutsky SG, Kamaraju AK, Levy AM, Chebath J, Revel M. Activation of myelin genes during
transdifferentiation from melanoma to glial cell phenotype. J Biol Chem 2003;278(11):8960–8968.
[PubMed: 12643284]
Sobue G, Shuman S, Pleasure D. Schwann cell responses to cyclic AMP: proliferation, change in shape,
and appearance of surface galactocerebroside. Brain Res 1986;362(1):23–32. [PubMed: 3002553]
Srinivasan R, Jang SW, Ward RM, Sachdev S, Ezashi T, Svaren J. Differential regulation of NAB
corepressor genes in Schwann cells. BMC Mol Biol 2007;8:117. [PubMed: 18096076]
Srinivasan R, Mager GM, Ward RM, Mayer J, Svaren J. NAB2 represses transcription by interacting
with the CHD4 subunit of the nucleosome remodeling and deacetylase (NuRD) complex. J Biol Chem
2006;281(22):15129–15137. [PubMed: 16574654]
Stolt CC, Lommes P, Friedrich RP, Wegner M. Transcription factors Sox8 and Sox10 perform non-
equivalent roles during oligodendrocyte development despite functional redundancy. Development
2004;131(10):2349–2358. [PubMed: 15102707]
Svaren J, Sevetson BR, Apel ED, Zimonjic DB, Popescu NC, Milbrandt J. NAB2, a corepressor of NGFI-
A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli. Mol Cell Biol 1996;16
(7):3545–3553. [PubMed: 8668170]
Svaren J, Sevetson BR, Golda T, Stanton JJ, Swirnoff AH, Milbrandt J. Novel mutants of NAB
corepressors enhance activation by Egr transactivators. Embo J 1998;17(20):6010–6019. [PubMed:
9774344]
Swiers G, Patient R, Loose M. Genetic regulatory networks programming hematopoietic stem cells and
erythroid lineage specification. Dev Biol 2006;294(2):525–540. [PubMed: 16626682]
Swirnoff AH, Apel ED, Svaren J, Sevetson BR, Zimonjic DB, Popescu NC, Milbrandt J. Nab1, a
corepressor of NGFI-A (Egr-1), contains an active transcriptional repression domain. Mol Cell Biol
1998;18(1):512–524. [PubMed: 9418898]
Szigeti K, Garcia CA, Lupski JR. Charcot-Marie-Tooth disease and related hereditary polyneuropathies:
molecular diagnostics determine aspects of medical management. Genet Med 2006;8(2):86–92.
[PubMed: 16481890]
Svaren and Meijer Page 14
Glia. Author manuscript; available in PMC 2010 August 31.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Szigeti K, Wiszniewski W, Saifi GM, Sherman DL, Sule N, Adesina AM, Mancias P, Papasozomenos
S, Miller G, Keppen L, et al. Functional, histopathologic and natural history study of neuropathy
associated with EGR2 mutations. Neurogenetics 2007;8(4):257–262. [PubMed: 17717711]
Taveggia C, Pizzagalli A, Fagiani E, Messing A, Feltri ML, Wrabetz L. Characterization of a Schwann
cell enhancer in the myelin basic protein gene. J Neurochem 2004;91(4):813–824. [PubMed:
15525335]
Taveggia C, Zanazzi G, Petrylak A, Yano H, Rosenbluth J, Einheber S, Xu X, Esper RM, Loeb JA,
Shrager P, et al. Neuregulin-1 type III determines the ensheathment fate of axons. Neuron 2005;47
(5):681–694. [PubMed: 16129398]
Timmerman V, De Jonghe P, Ceuterick C, De Vriendt E, Lofgren A, Nelis E, Warner LE, Lupski JR,
Martin JJ, Van Broeckhoven C. Novel missense mutation in the early growth response 2 gene
associated with Dejerine-Sottas syndrome phenotype. Neurology 1999;52(9):1827–1832. [PubMed:
10371530]
Topilko P, Levi G, Merlo G, Mantero S, Desmarquet C, Mancardi G, Charnay P. Differential regulation
of the zinc finger genes Krox-20 and Krox-24 (Egr-1) suggests antagonistic roles in Schwann cells.
J Neurosci Res 1997;50(5):702–712. [PubMed: 9418958]
Topilko P, Schneider-Maunoury S, Levi G, Baron-Van Evercooren A, Chennoufi AB, Seitanidou T,
Babinet C, Charnay P. Krox-20 controls myelination in the peripheral nervous system. Nature
1994;371(6500):796–799. [PubMed: 7935840]
Topilko P, Schneider-Maunoury S, Levi G, Trembleau A, Gourdji D, Driancourt MA, Rao CV, Charnay
P. Multiple pituitary and ovarian defects in Krox-24 (NGFI-A, Egr-1)-targeted mice. Mol
Endocrinol 1998;12(1):107–122. [PubMed: 9440815]
Verheijen MH, Chrast R, Burrola P, Lemke G. Local regulation of fat metabolism in peripheral nerves.
Genes Dev 2003;17(19):2450–2464. [PubMed: 14522948]
Warner LE, Mancias P, Butler IJ, McDonald CM, Keppen L, Koob KG, Lupski JR. Mutations in the
early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet
1998;18(4):382–384. [PubMed: 9537424]
Warner LE, Svaren J, Milbrandt J, Lupski JR. Functional consequences of mutations in the early growth
response 2 gene (EGR2) correlate with severity of human myelinopathies. Hum Mol Genet 1999;8
(7):1245–1251. [PubMed: 10369870]
Wegner M, Stolt CC. From stem cells to neurons and glia: a Soxist's view of neural development. Trends
Neurosci 2005;28(11):583–588. [PubMed: 16139372]
Wissmuller S, Kosian T, Wolf M, Finzsch M, Wegner M. The high-mobility-group domain of Sox
proteins interacts with DNA-binding domains of many transcription factors. Nucleic Acids Res
2006;34(6):1735–1744. [PubMed: 16582099]
Wrabetz L, D'Antonio M, Pennuto M, Dati G, Tinelli E, Fratta P, Previtali S, Imperiale D, Zielasek J,
Toyka K, et al. Different intracellular pathomechanisms produce diverse Myelin Protein Zero
neuropathies in transgenic mice. J Neurosci 2006;26(8):2358–2368. [PubMed: 16495463]
Yokoyama A, Wang Z, Wysocka J, Sanyal M, Aufiero DJ, Kitabayashi I, Herr W, Cleary ML. Leukemia
proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to
regulate Hox gene expression. Mol Cell Biol 2004;24(13):5639–5649. [PubMed: 15199122]
Yoon C, Korade Z, Carter BD. Protein Kinase A-Induced Phosphorylation of the p65 Subunit of Nuclear
Factor-{kappa}B Promotes Schwann Cell Differentiation into a Myelinating Phenotype. J Neurosci
2008;28(14):3738–3746. [PubMed: 18385332]
Zhong H, Voll RE, Ghosh S. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional
activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1998;1
(5):661–671. [PubMed: 9660950]
Zorick TS, Syroid DE, Brown A, Gridley T, Lemke G. Krox-20 controls SCIP expression, cell cycle exit
and susceptibility to apoptosis in developing myelinating Schwann cells. Development 1999;126
(7):1397–1406. [PubMed: 10068633]
Svaren and Meijer Page 15
Glia. Author manuscript; available in PMC 2010 August 31.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. Outline of a gene regulatory network of myelin-associated Schwann cell differentiation
The major transcription factors involved in the promyelinating to myelinating transition are
depicted with their regulatory relationship. Arrows indicate activation while blunt lines indicate
repression. This regulatory pathway culminates in induction of several genes in myelinating
Schwann cells, such as Myelin protein zero (Mpz), Myelin basic protein (Mbp), Connexin 32
(Cx32), and HMG CoA reductase. See text for further details.
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Figure 2. The POU domain transcription factors Oct6/Scip and Brn2 regulate the timing and rate
of the promyelin to myelinating transition
A. Toluodine Blue stained cross-sections of wildtype (left panel), Oct6 mutant (middle panel)
and Oct6/Brn2 mutant nerves at 16 days of postnatal development. Double Oct6/Brn2 mutant
Schwann cells are arrested at the promyelin stage of differentiation while around 70% of Oct6
mutant Schwann cells are stalled at this stage. In wildtype nerves all Schwann cell have gone
on to myelinate their associated axon. B. Quantification of the promyelinating to myelinating
transition. The graphical representation demonstrates the dramatic reduction in rate and altered
kinetics of this cellular transition. Promyelin and myelin figures were counted in electron
micrographs at 2600× magnification. At least 250 axons were scored per genotype at the
indicated timepoint.
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Figure 3. Sites of Krox20/Egr2 function
In panel A, the configuration of Krox20/Egr2 binding sites in the Connexin 32 and Mpz genes
is diagrammed. The promoter element of Connexin 32 and intron element of Mpz are
synergistically activated by Egr2 and Sox10, and similar configurations of sites are found in
the Mbp and Mag genes.
In panel B, various EGR2 mutations associated with human peripheral neuropathies are
diagrammed. For exact details, refer to the Inherited Peripheral Neuropathies Mutation
Database (http://www.molgen.ua.ac.be/CMTMutations/). Dominant mutations have been
found in all three zinc fingers, and they generally impair DNA-binding by EGR2. In addition,
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a recessive mutation in the NAB-binding domain was identified in one family. Loss of NAB
binding is expected to result in defective targeting of the NuRD chromatin remodeling complex.
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